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ABSTRACT
Objectives: Epidural analgesia is commonly used for relieving labor pain in contemporary clinical practice. The rate of 
pregnant women who request epidural analgesia during labor has been increasing annually, leading to a debate on the 
effect of epidural analgesia on maternal or neonatal outcomes.
Material and methods: The medical records of nulliparous women with a term singleton pregnancy from January to 
December 2019 at the Affiliated Hospital of Zunyi Medical University were retrospectively reviewed. The women were di-
vided into those who received epidural analgesia during delivery and those who did not receive it. Maternal and neonatal 
outcomes were assessed.
Results: A total of 528 women met the inclusion criteria. The overall labor analgesia rate was 43.0% (227). Women with 
epidural analgesia had a significantly longer second stage [34.5 (22.8–65.3) vs 27.0 (18.0–41.3) min, p < 0.001] and total 
duration of labor [698.5 (493.5–875.0) vs 489.5 (344.0-676.3) min, p < 0.001] compared with those without epidural. There 
were no significant relationships between epidural analgesia and the normal vaginal delivery rate, the incidence of episi-
otomy, and other adverse maternal or neonatal outcomes (p > 0.05).
Conclusions: Epidural analgesia can prolong the second stage of labor, but this is no increased risk for both mother and 
neonate.
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INTRODUCTION
Labor pain is one of the most common pains, which could 
cause a series of neurophysiological changes such as the 
increase of maternal oxygen stress hormones, the increase 
of blood pressure and the decrease of fetal oxygen transport, 
thus may affecting maternal and fetal well-being [1]. 
Epidural analgesia (EA) is currently one of the most ef-
fective ways of providing excellent intrapartum analgesia for 
pregnant women [2, 3]. In recent years, the rate of parturi-
ents who request EA during labor has widely increased, with 
a rate of 20–70% of all deliveries [4–7]. Since introduction 
of EA into the field of labor analgesia, attention has been 
paid to the effect of EA and pain relief in labor on maternal 
and neonatal outcomes. However, this effect of EA and pain 
relief in labor is controversial. Several studies have shown 
that beneficial analgesic effects come at the expense of pro-
longed labor, and an increase in instrumental vaginal deliv-
ery and emergency cesarean section, among others [8–11]. 
With regard to analgesic effects on the newborn, the existing 
literature on the relationship between EA and neonatal 
outcomes are equivocal [12–15]. In addition, whether the 
increase in maternal or neonatal morbidity is a consequence 
of EA is unclear. Anesthetic effects on maternal and neonatal 
outcomes continue to be investigated. Current and future 
work in these areas may improve clinicians’ ability to indi-
vidualize obstetric anesthesia treatment.
The aim of this study was to determine the effect of EA on 
maternal-neonatal outcomes regarding the period of labor.
MATERIAL AND METHODS
The study was conducted in accordance with the Dec-
laration of Helsinki. The study protocol was approved by 
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the Ethics Committee of the Affiliated Hospital of Zunyi 
Medical University, Guizhou, China (KLL-2020-015). Informed 
consent was waived owing to the retrospective nature of 
the study design. The study was performed in the Affiliated 
Hospital of Zunyi Medical University.
The reference population was composed of a group 
of nulliparous women with a term singleton pregnancy 
(≥ 37 weeks’ gestation) who received care during childbirth 
in the Affiliated Hospital of Zunyi Medical University from 
January to December 2019. The exclusion criteria were as 
follows: planned surgical delivery (elective cesarean sec-
tion), multipara, gestation < 37 weeks, multiple pregnancies, 
intrauterine fetal demise, and other anesthetic combina-
tions. The study population was determined using these 
criteria of exclusion (Fig. 1).
Mothers were divided into the epidural and non-epi-
dural groups according to whether they received analgesia 
by their choice. EA was performed in women when they re-
quested it, regardless of the size of cervical dilatation during 
the labor period. The epidural space was located between 
L2 and L3, and the epidural catheter was inserted into the 
epidural space for 3 cm. 8 mL 0.1% ropivacaine with 4 μg 
sufentanil was given as loading dose. An epidural catheter 
was situated and connected to a patient-controlled epidural 
analgesia (PCEA) pump containing solutions of ropivacaine 
0.1% with sufentanil 0.5 μg/mL. The PCEA regimen was as 
follows: 8 mL/h for continuous infusion, 8 mL at a bolus dose, 
and 30 min for locking [16]. PCEA was stopped at the end 
of the second stage of labor, and the catheter was removed 
two hours after delivery.
To collect the data, we used electronic medical records 
of the patients under study. Demographic data that were 
collected included maternal age, height, weight, gesta-
tional weeks, and complications. Maternal complications 
were defined as follows. Hypertension included essential 
or gestational hypertension or pre-eclampsia. Diabetes was 
defined as gestational diabetes, type 1 diabetes or type 
2 diabetes. Abnormal results of thyroid function examina-
tion could be diagnosed as thyroid disease. Anemia was 
defined as hemoglobin concentration < 110 g/L. Maternal 
outcomes included the type of delivery (spontaneous or in-
strumental vaginal delivery, or emergency cesarean section), 
meconium-stained amniotic fluid, episiotomy, duration of 
the first and second stages of labor and the total duration of 
labor, the amount of postpartum hemorrhage, and length 
of postpartum hospital stay. Neonatal data included the 
Apgar score at 1, 5, and 10 min, a 5-min Apgar score ≤ 7, 
and neonatal intensive care unit admission.
Statistical analyses were performed using the Statisti-
cal Package for Social Sciences (SPSS™), Windows version 
23.0 (IBM Corp., Armonk, NY, USA). First, the Shapiro–Wilk 
test was used to assess normal distribution of the data. 
Because of a lack of agreement with normal distribution, 
descriptive statistics analysis was performed using fre-
quencies and percentages for categorical variables and 
the median and interquartile range for quantitative vari-
ables. Bivariate analysis was then performed on the obstetric 
history and maternal or neonatal outcomes with use of EA 
(no/yes), using Fisher’s exact test or Pearson’s chi-square 
test for categorical variables and the Mann–Whitney U test 
for quantitative variables. For statistical tests, a value of 
p < 0.05 was considered to indicate statistical significance.
RESULTS
The reference population consisted of 4085 pregnant 
women of whom 2296 (56.2%) were excluded for elective 
Figure 1. Flow chart of women in the study
All deliveries n = 4085
Vaginal delivery n = l 789
Elective cesarean section n = 2296
Excluded (n = 1261)
• Multipara: 893
• Gestations under 37 weeks: 143
• Multiple pregnancy: 29
• Intrauterine fetal demise: 15
• Other anesthetic combinations: 181
Eligible criteria n =  528
Epidural group n = 227  Non-epidural group n = 301
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cesarean section and 1261 (30.9%) for various reasons, with 
a final total of 528 (12.9%) pregnant women. The study 
cohort was divided into the epidural group (227 women) 
and non-epidural group (301 women). The overall epidural 
rate was 43.0% (Fig. 1).
Women who received EA were more likely to be older 
compared with those without an epidural (p < 0.01). There 
were no differences in maternal height, weight, gestational 
age, and complications between the two groups. Demo-
graphics of the women are shown in Table 1.
Maternal outcomes are shown in Table 2. The times of 
the first (p < 0.001) and second (p < 0.001) stages of labor 
were longer in the epidural group than in the non-epidural 
group. Additionally, the total duration of labor was signifi-
cantly longer in the epidural group than in the non-epidural 
group (p < 0.001). However, there was no significant differ-
ence in the method of delivery between the groups. Ad-
ditionally, the rate of spontaneous vaginal delivery. The 
amount of postpartum hemorrhage and the mother’s 
hospital stay after delivery were not significantly different 
between the groups.
Regarding neonatal outcomes, there were no signifi-
cant differences in the Apgar score at 1, 5, and 10 min, 
and admission to the neonatal ward between the two 
groups (Tab. 3).
DISCUSSION
In this study, we found that EA was associated with long-
er duration of the second and total stages of labor. However, 
this did not affect the normal vaginal delivery rate, the inci-




No (n = 301) Yes (n = 227)
Maternal age [years] 26.0 (23.0–28.0) 27.0 (25.0–29.0)  < 0.01
Maternal height [cm] 158.0 (155.5–160.0) 158.0 (155.0–162.0) 0.29
Maternal weight [kg] 67.0 (60.0–72.3) 67.0 (62.0–72.0) 0.66
Gestational week, [weeks ± days] 39.6 (38.9–40.3) 39.7 (39.0–40.3) 0.19
Complications
Hypertension 6 (2.0) 3 (1.3) 0.56
Diabetes 32 (10.6) 33 (14.5) 0.18
Thyroid disorders 37 (12.3) 25 (11.0) 0.65
Anemia 56 (18.6) 28 (12.3) 0.05
Data are presented as n (%) or median (25th–75th percentiles); Diabetes — gestational diabetes mellitus, type 1 diabetes mellitus, or type 2 diabetes mellitus; 
hypertension — essential or gestational hypertension or pre-eclampsia; thyroid disorders — abnormal results of thyroid function tests; anemia — a concentration of 
hemoglobin < 110 g/L




No (n = 301) Yes (n = 227)
Type of delivery, n (%)
Normal Vaginal 241 (80.0) 196 (86.3) 0.06
Instrumental 5 (1.7) 2 (0.9) 0.44
Emergency CS 55 (18.3) 29 (12.8) 0.09
Meconium-stained amniotic fluid 81 (26.9) 54 (23.8) 0.42
Episiotomy* 122 (49.6) 92 (46.5) 0.51
First stage of labor duration [minutes] 445.0 (306.0–621.3) 655.0 (454.3–820.5) < 0.001
Second stage of labor duration [minutes] 27.0 (18.0–41.3) 34.5 (22.8–65.3) < 0.001
Total time of labor [minutes] 489.5 (344.0–676.3) 698.5 (493.5–875.0) < 0.001
Postpartum haemorrhage
< 0.5 L 244 (81.1) 197 (86.8) 0.79
≥  0.5 L 57 (18.9) 30 (13.2) 0.79
Maternal postnatal length of stay 2 (2–3) 2 (1–2) 0.21
CS — cesarean section; *Women who achieved a vaginal birth
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dence of episiotomy, and other adverse maternal or neona-
tal outcomes. Our results are consistent with recent studies 
that EA during delivery does not increase the rate of vaginal 
delivery, and EA during delivery is safe for both mothers and 
fetuses [17, 18]. A 2018 Cochrane review suggested that EA 
had no effect on the risk of cesarean section [19]. This review 
also showed that EA did not appear to have an immediate 
effect on neonatal status as determined by Apgar scores 
or in admission to neonatal intensive care. These review 
findings are in contrast to those of the Cochrane review of 
2011 [8]. Similarly, we found that although the second stage 
of labor in the epidural group was longer compared with 
that in the non-epidural group, the instrumental delivery 
rate, emergency cesarean section, and neonatal outcomes 
were similar between the two groups. However, unlike our 
study, previous studies showed that while a longer second 
stage of labor may increase vaginal delivery rate, this may 
be at the expense of increasing maternal and neonatal 
morbidity [20, 21].
Because of concern of a prolonged second stage of 
labor and its adverse outcomes, some obstetric nurses ask 
to reduce or terminate the epidural infusion rate in order to 
improve the maternal expulsive efforts in the second stage 
of labor [22]. This practice varies from center to center, but 
it is reported to occur in 46% of deliveries (range: 14–85%) 
[22, 23]. Increased maternal pain or decreased satisfaction 
with EA may be balanced with the successful benefits of 
vaginal delivery. However, this is not an ethical solution. 
Chestnut et al. [24], found that continuous epidural infu-
sion of 0.0625% bupivacaine had no effect on the duration 
of the second stage of labor. This finding suggested that 
there should be a dose-response relationship between 
the concentration of epidural local anesthetics and the ef-
fect of the second stage of labor. These authors’ findings 
are similar to recent findings that minimum local analge-
sic concentrations of epidural sufentanil or ropivacaine 
provided satisfactory and safe analgesia for parturients, 
while they had a low incidence rate of side effects [18, 25]. 
The potential dose-response mechanism of EA on the suc-
cess of the second stage of labor needs further study. We 
used a low concentration of ropivacaine (1%) with a relative 
potency of about 0.06% bupivacaine [26]. We found that the 
second stage of labor in the epidural group was 34.5 min 
(range: 22.8–65.3 min) compared with 27.0 min (range: 
18.0–41.3 min) in the non-epidural group. Interestingly, 
we found that the instrumental delivery and emergency 
cesarean section rates were similar between the epidural 
and non-epidural groups.
Due to the nature of our research, it has some limita-
tions, which are inherent in retrospective research and 
may be the cause of some bias. Data, such as maternal 
satisfaction and dose-response analyses, were missing, 
which lead to difficultly in further analyzing the underlying 
reasons and mechanisms of epidural-related maternal or 
neonatal outcomes. We also did not clarify whether EA is 
a risk factor, or whether other factors related to analgesia 
are the causes of adverse outcomes. We plan to add fur-
ther monitoring in future studies. In addition, the small 
sample size of this study is a limitation. Therefore, we need 
to further increase the sample size in the future to further 
verify our results.
CONCLUSIONS
EA can prolong the duration of labor, but there is no 
increase in the normal vaginal delivery rate or incidence of 
episiotomy, as well as no increase in other adverse effects 
in mothers or newborns. In summary, EA may be safe for 
the mother and neonate.
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No (n = 301) Yes (n = 227)
Apgar score at 1 min 10 (10–10) 10 (10–10) 0.56
Apgar score at 5 min 10 (10–10) 10 (10–10) 0.93
Apgar score at 10 min 10 (10–10) 10 (10–10) 0.88
5-min Apgar score ≤ 7 1 (0.3) 1 (0.4) 0.84
NICU admission 62 (20.6) 47 (20.7) 0.98
NICU — neonatal intensive care unit
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